Intech Biopharm Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 2.57 million compared to TWD 14.05 million a year ago. Net loss was TWD 75.06 million compared to TWD 71.71 million a year ago. Basic loss per share from continuing operations was TWD 0.65 compared to TWD 0.71 a year ago. Diluted loss per share from continuing operations was TWD 0.65 compared to TWD 0.71 a year ago. Basic loss per share was TWD 0.65 compared to TWD 0.71 a year ago. Diluted loss per share was TWD 0.65 compared to TWD 0.71 a year ago.
For the nine months, sales was TWD 19.43 million compared to TWD 25.37 million a year ago. Net loss was TWD 228.69 million compared to TWD 221.89 million a year ago. Basic loss per share from continuing operations was TWD 1.97 compared to TWD 2.21 a year ago. Diluted loss per share from continuing operations was TWD 1.97 compared to TWD 2.21 a year ago. Basic loss per share was TWD 1.97 compared to TWD 2.21 a year ago. Diluted loss per share was TWD 1.97 compared to TWD 2.21 a year ago.